作者
Garry G Graham, Jeroen Punt, Manit Arora, Richard O Day, Matthew P Doogue, Janna K Duong, Timothy J Furlong, Jerry R Greenfield, Louise C Greenup, Carl M Kirkpatrick, John E Ray, Peter Timmins, Kenneth M Williams
发表日期
2011/2/1
期刊
Clinical pharmacokinetics
卷号
50
期号
2
页码范围
81-98
出版商
Adis International
简介
Metformin is widely used for the treatment of type 2 diabetes mellitus. It is a biguanide developed from galegine, a guanidine derivative found in Galega officinalis (French lilac). Chemically, it is a hydrophilic base which exists at physiological pH as the cationic species (>99.9%). Consequently, its passive diffusion through cell membranes should be very limited. The mean ± SD fractional oral bioavailability (F) of metformin is 55 ± 16%. It is absorbed predominately from the small intestine.
Metformin is excreted unchanged in urine. The elimination half-life (t1/2) of metformin during multiple dosages in patients with good renal function is approximately 5 hours. From published data on the pharmacokinetics of metformin, the population mean of its clearances were calculated. The population mean renal clearance (CLR) and apparent total clearance after oral administration (CL/F) of metformin were …
引用总数
20112012201320142015201620172018201920202021202220232024134875839912412111610313314012912949
学术搜索中的文章
GG Graham, J Punt, M Arora, RO Day, MP Doogue… - Clinical pharmacokinetics, 2011